64例淋巴瘤细胞白血病患者的病理免疫组化及骨髓流式免疫分型分析及临床意义  

Comparison of Pathological Immunohistochemistry and Bone Marrow Flow Cytometry in 64 Patients with Lymphoma Cell Leukemia and Its Clinical Significance

作　　者：宋丽娜[1] 王冲[1] 洪英霞[1] 王瑞[1] SONG Lina;WANG Chong;HONG Yingxia(The First Affiliated Hospital of Zhengzhou University,Zhengzhou,450052)

机构地区：[1]郑州大学第一附属医院,450052

出　　处：《实用癌症杂志》2022年第8期1381-1384,共4页The Practical Journal of Cancer

摘　　要：目的分析淋巴瘤细胞白血病(LCL)患者骨髓流式免疫及病理免疫组化分型及临床意义。方法64例LCL患者,均行病理免疫组化及流式细胞术(FC)检查。分析免疫组化及骨髓流式免疫分型各抗原表达情况,同时进行随访,分析LCL患者生存周期特点。结果免疫组化及骨髓流式免疫分型均显示,25例T淋巴细胞型,39例B淋巴细胞型;免疫组化各抗原表达结果显示,T淋巴细胞型表达率最高的抗原为CD7,占比100.00%,其次为CD3,占比60.00%;B淋巴细胞型表达率最高的抗原为CD19,占比94.87%,其次为CD20,占比56.41%;骨髓流式免疫各抗原表达结果显示,T淋巴细胞型表达率最高的抗原为CD7,占比100.00%,其次为CD3,占比60.00%;B淋巴细胞型表达率最高的抗原为CD19,占比94.87%,其次为CD20,占比56.41%;25例T淋巴细胞型患者生存周期为1~40个月不等,中位生存周期为19.78个月,伴CD3表达缺失中位生存期为12.98个月,不伴CD3表达缺失中位生存期为9.55个月;39例B淋巴细胞型患者生存周期为3~60个月不等,中位生存周期为27.75个月,伴CD20表达缺失中位生存期为7.16个月,不伴CD20表达缺失中位生存期为32.11个月。结论病理学诊断对临床诊断及治疗LCL具有重要的作用,且辅以髓流式免疫分型可进一步提高LCL诊断准确性,两者相互补充,对于临床治疗有一定的指导意义。Objective To analyze the results of flow cytometry and pathological immunohistochemistry in bone marrow of patients with lymphoma cell leukemia(LCL)and its clinical significance.Methods 64 patients with LCL treated in our hospital from June 2014 to October 2016 were examined by pathological immunohistochemistry and flow cytometry(FC).The antigen expression of immunohistochemistry and bone marrow flow immunotyping were analyzed,and the survival cycle characteristics of LCL patients were analyzed.Results immunohistochemistry and bone marrow flow cytometry showed that 25 cases were T lymphocyte type and 39 cases were B lymphocyte type;The results of immunohistochemistry showed that the antigen with the highest expression rate of T lymphocyte type was CD7,accounting for 100.00%,followed by CD3,accounting for 60.00%;The antigen with the highest expression rate of B lymphocyte type was CD19,accounting for 94.87%,followed by CD20,accounting for 56.41%;The results of bone marrow flow cytometry showed that the antigen with the highest expression rate of T lymphocyte type was CD7,accounting for 100.00%,followed by CD3,accounting for 60.00%;The antigen with the highest expression rate of B lymphocyte type was CD19,accounting for 94.87%,followed by CD20,accounting for 56.41%;The median survival period of 25 patients with T lymphocyte type ranged from 1 to 40 months,with a median survival period of 19.78 months,12.98 months with loss of CD3 expression and 9.55 months without loss of CD3 expression;The survival period of 39 patients with B lymphocyte type ranged from 3 to 60 months,with a median survival period of 27.75 months.The median survival period with loss of CD20 expression was 7.16 months,and the median survival period without loss of CD20 expression was 32.11 months.Conclusion Pathological diagnosis plays an important role in clinical diagnosis and treatment of LCL,and myeloflow immunotyping can further improve the diagnostic accuracy of LCL.They complement each other and have certain guiding significance for clinica

关 键 词：淋巴瘤细胞白血病 病理免疫组化 骨髓流式免疫 

分 类 号：R733.7[医药卫生—肿瘤]